Dr. Stevan Pecic

Office: MH-582E
Phone: (657) 278-2471

Email: specic@fullerton.edu

Lab:  DBH-179
Phone:  (657) 278-5295

Stevan Pecic

Assistant Professor Medicinal and Bioorganic Chemistry


Research Interests 

Development of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics using traditional medicinal chemistry techniques (in silico drug design, synthesis, structure-activity relationship (SAR) studies and in vitro biological assays). We are also focused on the identification of DNA-aptameric sensors for small molecules in so-called structure-switching format using SELEX procedure. We are in particular interested in aptamers for small molecules such as steroids and drugs that regulate pain and inflammation. Aptamers generated via SELEX hold promise for bioimaging, drug development, drug discovery, disease diagnosis, hazard detection, food inspection and many other biomedical applications.



Postdoctoral- Columbia University Medical Center, New York

Ph.D. The City University of New York, Graduate School and University Center

M.Phil. The City University of New York, Graduate School and University Center

Dipl.Pharm. Faculty of Pharmacy, University of Belgrade, Serbia


Selected Publications

For a full list of publications please visit the Pecic Lab WebsiteOpens in new window

Alizadeh, J; da Silva Rosa, SC; Weng, X; Jacobs, J; Lorzadeh, S; Ravandi, A; Vitorino, R; Pecic, S; Zivkovic, A; Stark, H; Shojaei, S; Ghavami, S. Ceramides and Ceramide Synthases in Cancer: Focus on Apoptosis and Autophagy.Opens in new window European Journal of Cell Biology (2023),151337. 

Stec, J; Xie, S; Alshukri, L; Kang, GJ; Hudson, PK; Pecic, S. Convenient synthesis and in vitro activity of oxalyl bis(benzenesulfonylhydrazides) and related compoundsOpens in new window . Results in Chemistry (2023), 5, 100860.

Angelia, J; Weng, X; Solomatov, A; Chin, C; Fernandez, A; Hudson, PK; Morisseau, C; Hammock, BD; Kandasamy, R; Pecic, S. Structure-activity relationship studies of benzothiazole-phenyl analogs as multi-target ligands to alleviate pain without affecting normal behaviorOpens in new window . Prostaglandins & Other Lipid Mediators (2023), 164, 106702.

Naeimi, R; Najafi, R; Molaei, P; Amini, R; Pecic, S. Nanoparticles: The future of effective diagnosis and treatment of colorectal cancer?Opens in new window European Journal of Pharmacology (2022), 175350.

Eshraghi, M.; Ahmadi, M.; Afshar, S.; Lorzadeh, S.; Adlimoghaddam, A.; RezvaniJalal, N.; West, R.; Dastghaib, S.; Igder, S.; Torshizi, S.R.N.; Mahmoudzadeh. A.; Mokarram, P.; Madrakian, T.; Albensi, B. C.; Los, M.J.; Ghavami, S.; Pecic, S. Enhancing Autophagy in Alzheimer's Disease Through Drug Repositioning. Pharmacology & Therapeutics (2022), 108171. 

Stec, J; Pecic, S. Facile synthesis of the fungus-derived natural products: N,N′-dipalmitoleyl urea (C16:1) and N,N′-dioleyl urea (C18:1)Opens in new window , Natural Product Research (2022), 36 (8), 2158-2165.

Makarian, M.; Gonzalez, M.; Salvador, SM.; Lorzadeh, S.; Hudson, P.K.; Pecic, S. Synthesis, Kinetic Evaluation and Molecular Docking Studies of Donepezil-Based Acetylcholinesterase Inhibitors. Journal of Molecular Structure (2022), 1247, 131425. 

Wilt, S.; Kodani, S.; Valencia, L.; Hudson, P. K.; Sanchez, S.; Quintana, T.; Morisseau, C.; Hammock, B. D.; Kandasamy, R.; Pecic, S. Further Exploration of the Structure-Activity Relationship of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. Bioorganic & Medicinal Chemistry (2021), 51, 116507. 


Courses Taught

Spring 2024 Office Hours

Wed 3pm-4pm.